Despite official support for the efficacy of cholesterol reduction, considerable controversy exists, and metaanalyses of this topic have produced conflicting results. The authors assessed the variability of meta-analyses, evaluating the cardiovascular value of cholesterol reduction while attempting to explain the variability. Metaanalyses were identified by electronic search and citation tracking. Included were those conducted prior to 1995 that dealt with cholesterol reduction and total mortality, cardiovascular mortality, or nonfatal cardiovascular disease. In addition to extracting odds ratios for total mortality, cardiovascular mortality, and nonfatal cardiovascular disease, the authors encoded methodological variables, publication variables, and data concerning investigators' backgrounds. Twenty-three meta-analyses were reviewed, and 15 concluded that cholesterol reduction was beneficial. Summary odds ratios for total mortality were heterogeneous, generally failing to support the value of cholesterol reduction. Odds ratios depended on inclusion criteria and investigator variables. Odds ratios for cardiovascular mortality and for nonfatal cardiovascular disease were more homogeneous and supported the value of cholesterol reduction. Methodologically better meta-analyses tended to report more beneficial odds ratios. Although "supportiveness" of the value of cholesterol reduction was associated with inclusion/exclusion criteria and publication variables, the primary outcome variable related to supportiveness was the statistical significance of the odds ratios for cardiovascular mortality. (1) and of other articles concerning the decrease in morbidity and mortality associated with cholesterol reduction, most official guidelines for the primary prevention of heart disease have included an aggressive approach to the treatment of elevated serum cholesterol (2-6). This recommendation occurred in spite of continued controversy about the results of studies regarding the efficacy of cholesterol reduction.
approach to cholesterol reduction. Ravnskov concluded that claims of reduced mortality were based on preferential citation of supportive trials four to seven times more often than unsupportive trials and that this preferential citation was not based on the quality of the trials (9) . In addition, different metaanalyses that included the same studies found conflicting results (8) (9) (10) .
As there is controversy concerning the value of cholesterol reduction, controversy also exists regarding the value of meta-analysis. Critics have cited several potential weaknesses: 1) bias in the selection of studies, 2) heterogeneity of study designs, 3) interpretability of p values, 4) publication bias, and 5) investigator bias (11) . Consequently, meta-analytic methodology may not be developed adequately enough to enable meta-analysis to serve as the basis for recommendations on efficacy (12) .
With these controversies in mind, we conducted this study to assess the quality of and variability in meta-analyses that, in terms of total mortality and both fatal and nonfatal coronary heart disease, considered the value of cholesterol reduction. This study attempted to explain conflicting meta-analytic results based on differences in methodology or bias.
MATERIALS AND METHODS

Procedure
In addition to using the six meta-analyses identified by Ravnskov (8) , we attempted to locate meta-analyses published prior to 1995 by conducting a computerized literature search (MEDLINE database) via the keywords "cholesterol reduction," "lipid reduction," "cardiovascular disease," and "mortality" and by reviewing bibliographies of the meta-analyses. The Cochrane Collaboration (13) was also contacted; seven of the meta-analyses that we had already found were unknown to them. However, the Collaboration did identify two meta-analyses that we had not located.
Meta-analyses were included if they investigated the relation between cholesterol reduction and total mortality, cardiovascular mortality, or nonfatal cardiovascular disease. Reviews that did not pool the results of studies or merely reiterated the results of a previous meta-analysis were excluded. When a single metaanalysis was reported as two separate articles focusing on different subgroups, the results were combined by using Tukey's jackknife technique (14) to provide an overall odds ratio. Twenty-three meta-analyses were included in our study and are listed in the Appendix. Information on the trials in each meta-analysis is available from the authors on request.
By using the literature on meta-analysis (15), we identified characteristics that could affect meta-analytic results. These characteristics are listed in table 1. We coded each meta-analysis independently; disagreements were resolved through discussion and consensus.
We determined that selection bias had been avoided if inclusion/exclusion decisions were made on the basis of only the methods section of the meta-analysis. We decided that investigators were blinded to the results if they encoded study variables on the basis of the methods section alone. A recent study failed to show that blinding readers had any effect on metaanalytic results (16) . Furthermore, meta-analyses were defined as having clearly defined protocols if they were reproducible from the description in the methods section. The availability of studies to each metaanalysis was determined by first compiling the list of relevant studies from bibliographies and all metaanalyses included (available from the authors on request). The meta-analyses rarely reported the closing dates of their literature searches. We assumed a 1-year delay in publication; thus, each meta-analysis was considered to have available to it all studies published until 1 year before the meta-analysis was published. If a nonincluded study was specified as being excluded from the analysis, it was labeled as excluded. The number of studies ignored in a meta-analysis was defined as the difference between the number of nonincluded but available studies and the number of excluded studies. Two publications were considered to be derived from the same study if experimental and/or control subjects overlapped. A meta-analysis was considered to have included >1 effect size per study if multiple effect sizes were included from multiple publications that described the same original subjects.
Outcome variables consisted of the odds ratios for treatment versus control groups for cholesterol reduction and 1) total mortality, 2) cardiovascular mortality, and 3) nonfatal cardiovascular disease. In addition, we also recorded whether individual meta-analytic odds ratios were statistically significant (p < 0.05). Finally, by using the study's abstract and conclusion only, we rated each meta-analysis as supportive or nonsupportive overall of a beneficial effect of cholesterol reduction.
In this study, we used meta-analytic quality as a variable. There is disagreement about the value of weighting effect sizes on the basis of study quality (17) (18) . However, there is agreement that study quality should be incorporated into meta-analyses (19) (20) , although concern about scoring systems and cutoffs exists (20) . In addition to being used as a weighting index, quality can be incorporated as an inclusion/exclusion criterion, plotted against effect size, or used to sequentially pool meta-analytic results based on quality (20) . Metaanalytic quality was measured by using the Overview Quality Assessment Questionnaire (21-22), a 10-item instrument that rates meta-analyses in nine methodological areas using a 1-7 scale (1 = very poor, 7 = exemplary). These areas include reporting and comprehensiveness of search procedures, reporting of inclusion criteria, avoidance of selection bias, reporting and appropriateness of validity criteria, reporting and appropriateness of combining methods, and whether the data support the conclusions. Finally, the overall scientific quality of the review is assessed. Unreported methods are assumed to be poor (21) . This approach is supported by the findings of Schulz et al. (23) that effect sizes differ little between studies in which criteria are inadequate versus unclear. Interrater reliability of the overall meta-analytic quality is suggested by intraclass correlations of >0.5 for single judges and >0.67 for two judges (22) . The validity of the overall rating of review quality also has been shown (21) . In our study, we assessed the association between meta-analytic quality and outcomes, investigator variables, and publication variables.
Because publication bias was possible, we plotted funnel graphs (24) of outcome measures against the number of included effect sizes. In addition, we compared the distributions of the p values for primary outcomes with normal distributions (25) . Evidence of bias was also sought through associations between out- come measures and publication variables. We used the year of publication, journal's country of origin, type of journal (general medical vs. specialty), journal's impact on the literature, immediacy of citation (26) , and type of publication (article, abstract, or letter to the editor).
We defined investigator bias as systematic deviation from the truth as a result of investigators' opinions or Am J Epidemiol Vol. 149, No. 5, 1999 feelings about the phenomenon studied. We also investigated the impact of author characteristics on outcomes. Characteristics of the first author included gender, academic degree(s), country of publication, age at publication, and whether he or she previously had published about cholesterol reduction (content expertise) or meta-analytic methodology (methodological expertise). Emphasis on the first author is consistent with the work of Oxman and Guyatt (21) . Taken as a group, the authors of each meta-analysis were described on the basis of the number of countries represented and the proportions of male investigators, physicians, and those who had previously published in the areas of cholesterol reduction or meta-analytic methodology. If evidence of prior publication could not be found, none was assumed. Data concerning investigators were derived from the articles themselves as well as from directories of medical organizations. Data on academic degrees and countries of origin were obtained for 70 percent and 95 percent of the investigators, respectively. By using first names, we determined gender for 84 percent of the investigators. Age at publication could be determined for only six first authors. Table 1 assesses interrater agreement between the two authors regarding coded variables; kappa statistics were used for nominal variables and intraclass correlations for continuous variables. Perfect agreement (kappa = 1.0) was obtained for 4 of 27 variables and excellent agreement (kappa > 0.8) for an additional 5. Of the remaining variables, good agreement (0.6 < kappa < 0.8) was obtained for 9 and fair agreement (0.4 < kappa < 0.6) for an additional 9. Agreement was poor (kappa < 0.4) for only 3 variables. All seven intraclass correlations were >0.7 with/? values of <0.01.
Interrater agreement
Analysis
When possible, odds ratios for each meta-analysis were extracted from the publication. Those not published were derived from Ravnskov (9) when possible. When meta-analyses presented odds ratios separately for drug and dietary studies without overall odds ratios, results were computed by using Tukey's jackknife technique (14) . The natural logarithmic transformation of odds ratios (InORs) was used during bivariate analyses. Odds ratios were considered significant if the 95 percent confidence interval did not include 1.00.
Homogeneity of odds ratios across meta-analyses was determined by using chi-square testing based on InORs and standard error (SE), and each meta-analysis was treated as if it were an individual trial
The overall weighted mean InORs were calculated for the tests of homogeneity
Univariate analyses were performed by using Fisher's exact test, the Mann-Whitney test, Kruskal-Wallis analysis of variance, and Spearman's correlation (r). Normality of p-value distributions was assessed by using Kolmogorov-Smirnov goodness-of-fit testing. A p value of <0.05 was deemed significant; 0.05 < p < 0.1 showed a trend toward significance. To identify variables that predict odds ratios independently, we performed stepwise multiple regression by using InORs as the outcome variable and variables that were significant on univariate analysis as predictors.
RESULTS
The methodological characteristics of the metaanalyses included in our study are shown in table 2. One meta-analysis, which supported a beneficial effect of cholesterol reduction, did not present any odds ratios and was published in abstract form only. Study characteristics across all 23 meta-analyses are summarized in table 3. We rated the quality of 11 of the metaanalyses as less than 4.0 (satisfactory-high quality) (data not presented). Eighteen meta-analyses investigated total mortality, 17 of which presented a p value or confidence interval. Fifteen meta-analyses assessed cardiovascular mortality, all of which included p values. Finally, 12 meta-analyses assessed nonfatal cardiovascular disease, 11 of which presented p values. Overall, 21 percent of the first authors and 14 percent of all investigators involved had methodological expertise, whereas 43 percent of the first authors and 26 percent of all investigators had content expertise. Figures 1-3 show the overall odds ratios and 95 percent confidence intervals for each meta-analysis assessed for total mortality, cardiovascular mortality, and nonfatal cardiovascular disease, respectively. Unlike for cardiovascular mortality and disease, the weighted (based on sample size) results for total mortality were heterogeneous (x\ = 47.85, df = 16, p < 0.001). Overall, 15 (65 percent) meta-analyses concluded that cholesterol reduction was beneficial (supportiveness).
The associations among methodological characteristics and odds ratios are addressed in table 4.
Comparisons not presented were not statistically significant. For total mortality, care taken in reporting unifactorial (inclusion of trials focusing on the effects of cholesterol reduction alone) or multifactorial criteria was associated with less beneficial odds ratios. Excluding primary prevention studies resulted in more beneficial odds ratios; excluding secondary prevention studies resulted in less beneficial odds ratios. Metaanalyses conducted by methodologically expert first authors or those from outside Scandinavia also reported a more beneficial effect. Because of the high preva- lence of cardiovascular disease in Scandinavian countries, whether the first author was Scandinavian might have affected his or her attitudes toward the study; however, to code first authors as Scandinavian or nonScandinavian was a post hoc decision. The greater the proportion of available studies that were included, the more beneficial the effect (r s = -0.46, p < 0.1). However, investigator variables also were associated with the odds ratio, which was inversely related to the number of authors {r s = -0.50, p < 0.05) and the proportion of authors who had meta-analytic experience (r s = -0.45, p < 0.1). Regression analysis showed that two variables, exclusion of secondary prevention and first author from outside Scandinavia, predicted less beneficial odds ratios for total mortality (F statistic = 13.61, p = 0.0011, R 2 = 0.66). For cardiovascular mortality, using only independent effect sizes resulted in more beneficial odds ratios. However, seeking studies from pharmaceutical companies also resulted in more beneficial odds ratios, as did ignoring more studies {r s = -0.72, p < 0.05). When the first author had a doctor of medicine (MD) degree or was younger than the other authors (j s = 1.0, p < 0.01), the odds ratio suggested more benefit from therapy. Regression analysis showed that seeking studies from pharmaceutical companies was the sole independent predictor of the odds ratio for cardiovascular mortality (F statistic = 42.39, p = 0.0002, R 2 = 0.82). For nonfatal cardiovascular disease, restricting inclusion to only randomized clinical trials and only unifactorial studies while using bibliographies in the search procedure resulted in more beneficial odds ratios. When the first author was from Scandinavia, the odds ratio suggested less benefit from therapy. Regression analysis showed that including only multifactorial studies independently predicted the odds ratio for nonfatal cardiovascular disease (F statistic = 13.28, p = 0.0054, R 2 = 0.55). When we compared meta-analyses that concluded that cholesterol reduction is beneficial (supportiveness) with those that did not, we found little difference in total mortality and nonfatal cardiovascular disease outcomes. However, 88 percent of supportive meta-analyses found a statistically significant odds ratio for cardiovascular mortality, whereas only 29 percent of the nonsupportive meta-analyses did. Supportive meta-analyses generally were better designed-they included only randomized clinical trials, included secondary prevention studies, and excluded studies allowing hormonal therapy-and were published in journals with less impact and immediacy. None of the nonsupportive meta-analyses included authors with meta-analytic expertise. Meta-analytic quality was not associated with methodological, publication, or investigator variables. The only significant finding was an association with year of publication (r = 0.39, p < 0.1). Sequential plots of cumulative odds ratios as reductions in quality showed no relation between quality and odds ratios for either cardiovascular mortality or nonfatal cardiovascular disease. For total mortality, the odds ratio showed that therapy was more beneficial as the quality decreased, until quality dropped to less than 5.5.
Meta-analytic quality was not related to any other outcome variables.
When the risk of publication bias was assessed, year of publication and publication type were not associated with any of the outcome variables. Funnel graphs did not suggest publication bias, and all p values for the odds ratios for total mortality, cardiovascular mortality, and nonfatal cardiovascular disease were distributed normally. However, 4 of the 10 meta-analyses in British journals were supportive of a beneficial effect Odds ratio FIGURE 1. Study results, from the meta-analyses included in this review, of the effect of cholesterol reduction on total mortality. Results are presented as the overall odds ratio (letter corresponding to the meta-analysis listed in the Appendix) and 95% confidence interval ( i--i ) for that particular meta-analysis. Meta-analysis N did not include the 95% confidence interval or sufficient information to calculate it.
compared with 11 of the 13 meta-analyses in nonBritish journals (Fisher's p = 0.039). The decision to focus on British versus non-British journals was post hoc.
DISCUSSION
Evaluation of meta-analysis
Although this study found homogeneity across meta-analyses in terms of odds ratios for cardiovascular mortality and disease, the odds ratios for total mortality were heterogeneous. The variability of metaanalytic results raises questions about the reliability and validity of this technique. Henry and Wilson (27) studied meta-analytic cohorts and found a high level of agreement in summary statistics. Meta-analyses evaluating the effects of beta blockers and streptokinase in the treatment of acute myocardial infarction have reported similar results (28) . Sequential application of meta-analysis has not demonstrated transiently significant results. However, when Chalmers et al. (29) reviewed outcomes of 20 meta-analytic cohorts, 10 were found to agree statistically and only 6 clinically, but differences were in degree, not direction. Other authors have questioned the reliability of metaanalysis. The potential fragility of results was demonstrated in a study of the role of aspirin in preventing myocardial infarction. Eliminating one study resulted in heterogeneity and a lack of statistical significance (19) . Replicated meta-analyses have reported different results (30) , and different meta-analyses have found different effect sizes even when the same data set was used (31) . Hence, the use of meta-analysis does not guarantee an invariate result. The validity of a meta-analytic result is also uncertain. Although the results of large trials agree with the results of metaanalyses of small trials (29, 32) , such agreement is not always observed (28) . Thus, the issues of the reliability and validity of meta-analysis as a technique are still unresolved. Even though heterogeneity in meta-analyses is common, its sources should be explored (33) . Such exploration may provide insights into the importance of study design, treatment, and study population, and identification of sources may be useful in planning future studies (34) . Potential sources of disagreement among meta-analyses include differences in the questions addressed, studies included, data abstracted, weighting of outcomes, aggregation methods, and inferences drawn (35) .
Although Chalmers et al. (28) emphasized the importance of the study quality of the randomized clinical trials included in a meta-analysis, 30 percent of meta-analyses do not report on study quality; none in our study assessed quality. Forty percent of metaanalyses use study quality as an inclusion criterion, and most of those remaining use study quality in subgroup analyses; rarely are effect sizes weighted by study quality (36) . Even though control of potential bias is associated with effect size (23, 37, 38) , other meta-analyses have reported little or no effect of study quality on results (39) . In one case, using study quality as an inclusion/exclusion criterion or weighting index had only a mild effect on odds ratios but no effect on p values (20) . Weighting study effect sizes by quality does not change the conclusions when either randomized or quasi-randomized studies are used (40) . Hence, although specific methodological features may influence effect size, overall study quality usually is not assessed and rarely influences results. However, the quality of reviews has been associated with results; whereas quality was positively associated with the benefits of spinal manipulation in treating back pain (41) , quality was inversely related to the benefits of analgesics (42) . Overall meta-analytic quality was not associated with any outcomes in this study.
As the effect sizes in meta-analyses can vary, so can interpretations of their results. Repeating a metaanalysis on the causal relation between steroids and peptic ulcer disease led to an attenuation of the original conclusions (43) . Studies of meta-analytic cohorts found that interpretation of results was a common source of disagreement between cohorts (27) . Although differences tend to be related to degree rather than to direction, there is more disagreement regarding interpretation (29) . Meta-analytic results can be overstated (11) , and there is a potential for bias when results are interpreted; meta-analysis can be used to editorialize (44) . Assendelft et al. (41) determined that a positive conclusion in reviews of spinal manipulation was related to review quality, completeness of the search, and having a spinal manipulator on the research team. Hedges (25) found that the conclusiveness of a meta-analysis was related to p values and was unrelated to the magnitude of the effect sizes, which we also found.
Conclusions may vary on the basis of the outcome used. Peto (45) emphasizes the need to include outcomes for both total and disease-specific mortality, but total mortality may not be a reliable outcome. If data are limited, disease-specific mortality may be more sensitive to real effects, more generalizable, and consequently more informative. However, diseaseoriented evidence, such as proof that an intervention lowers cholesterol, requires many assumptions before its value can be demonstrated. Patient-oriented evidence, such as proof that an intervention lowers total mortality, requires few assumptions and therefore is more applicable. A reduction in disease-specific morbidity/mortality lies in between (28) . In addition, a more focused meta-analysis is more valid (44) and of higher quality (21) . Compared with large clinical trials, meta-analyses of multiple small trials probably produce more generalizable results but may be less accepted by clinicians (46) . Randomized clinical trials can produce contradictory results; interpretation should consider unexpected outcomes, the frailty of double blinding, and the impact of regulatory variables, for example, compliance (47) . Just as these issues affect interpretation of randomized clinical trials, they also should be considered when interpreting meta-analyses.
Finally, how meta-analytic data are read may be the result of a unique, individual perception. When overall meta-analytic quality was used, the poorest intraclass correlation (0.4) reflected the degree to which the conclusions were supported by the data (22) . Consequently, the conclusion of the author(s) may vary considerably depending on the outcomes used and their p values. However, conclusions may be biased and are not always supported by the data. In our study, supportiveness appeared to be based on the significance of the odds ratio for cardiovascular mortality. Although the associations between supportiveness and inclusion/exclusion criteria suggest that supportive meta-analyses were designed better than nonsupportive meta-analyses, other design characteristics had the opposite association. Investigator and publication bias also may contribute to supportiveness.
Because interpretation of results is a subjective response to the outcomes, variability of conclusions may be a manifestation of investigator bias. All four major outcomes were associated with investigator variables. Rosenthal (48) catalogued evidence of the influence of investigator factors on subject responses; investigator characteristics and experience, modeling, and expectations can alter study results. Similarly, interpretation of results may depend on investigator characteristics. Reviewers tend to be more enthusiastic about treatments in their specialty (49) . Having a spinal manipulator on the research team has been associated with a positive conclusion in meta-analyses of spinal manipulation (41) . The quality of a metaanalysis depends on the number of investigators and the content and methodological expertise of the first author (21) . The need for meta-analysts to have expertise has been emphasized by McConaghy (30) . When this expertise translates into increased meta-analytic quality, then such expertise has a positive effect. However, when expertise is associated with outcome but is unrelated to meta-analytic quality, then expertise may be a source of bias, as we found in our study.
An association between funding source and study results may be a manifestation of investigator bias. Published studies funded by pharmaceutical companies versus other sources are more likely to find positive results (43) . Similarly, authors' opinions about oral hypoglycemics vary depending on whether they receive funding from manufacturers of oral hypoglycemics (49) . Although these cases may represent investigator bias, they also may be manifestations of publication bias if pharmaceutical companies prohibit publication of negative studies they have supported. When the search procedure included contacting pharmaceutical companies, the odds ratio for cardiovascular mortality was lower. This finding suggests that these companies may have reported studies selectively.
The existence of publication bias is well documented (50) . Not only do published and unpublished studies differ in effect sizes and p values (51) (52) (53) , but other forms of publication bias also exist. Abstracts differ from published research papers in effect size (54) and statistical significance (55) . In addition, randomized clinical trials with positive results versus those with negative results appear in more prominent journals (52) . However, controversy exists concerning what to do about the possibility of publication bias in metaanalysis. Evidence of publication bias should always be sought in a meta-analysis. Including unpublished data may not affect the results (23, 51) , but most metaanalysts recommend including unpublished studies (12, 28, 45) . They favor inclusion of unpublished data more than editors do (56) . In addition, randomized clinical trials in languages other than English also should be sought (57) .
The cause of publication bias is probably multifactorial. Even though reviewers are influenced by positive results, investigators often fail to submit studies because of negative results or a lack of interest (50) . Hence, publication bias also may be a form of investigator bias. Although there was no evidence in our study of unpublished meta-analyses that reported different results, publication variables were associated with supportiveness and significant odds ratios for total mortality. This study suggests that supportive versus nonsupportive meta-analyses tended to be published in non-British journals and journals with less impact and immediacy.
Limitations
This study has several limitations. Just as a metaanalysis should include all relevant studies to be complete, so must an analysis of meta-analyses include all relevant meta-analyses. Reliance on computer searches and bibliographic review can result in failure to identify studies. Funnel graphs and distributions of p values do not suggest publication bias.
Because study characteristics frequently were not presented, analyses of associations between study characteristics and outcomes may be misleading. Logic suggests that if a characteristic is not presented specifically, it should be assumed that the characteristic was not addressed or that the control for that particular source of bias was poor (21) . Some investigator variables, for example, age and gender, included sizable quantities of missing data. Hence, investigator variables may be related to design variables, although analysis of the associations between methodological expertise and design variables found that they were not significant.
There are statistical limitations as well. Because the meta-analyses frequently included the same clinical trials, the included studies overlapped. Analyses of the associations between study characteristics and outcomes lack sufficient statistical power. Real associations may have been missed because of statistical limitations. The use of multiple regression with small sample sizes is also questionable. Tests of homogeneity lack statistical power (18) .
Conclusions
This overview of meta-analyses on the benefits of cholesterol reduction supported the homogeneity of results for cardiovascular mortality and nonfatal cardiovascular disease. Odds ratios for total mortality were heterogeneous but suggested no benefit. However, meta-analyses focusing on secondary prevention showed more beneficial odds ratios for total mortality. Methodologically, most meta-analyses were described inadequately and raise concerns about the reliability of the current practice of meta-analysis. In addition, possible investigator bias was evident in all outcomes, and the journal of publication may depend on supportiveness. Supportiveness largely depended on one outcome: the p value for cardiovascular mortality. These results emphasize the need to include investigator and publication variables in meta-analyses.
